PTC Therapeutics, Inc.

PTCT Healthcare Biotechnology

PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024. In the quarter to June 2026, revenue grew 101.6%, EPS grew 221.7%, free cash flow grew 295.7% and total debt rose 21.6%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

59.24 1.75 −2.87%
Market cap
$5.1B
P/E
0.0×
Fwd P/E
110×
Dividend yield
—
F-score
7/9
Altman Z
1.86
Beneish M
−1.48
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
20.64% 101.97% (104.75%) (124.24%)

+8 more TTM periods

Piotroski F-Score
2 1 7 7
ROA
(1.30%) (6.76%) 29.66% 33.51%
ROIC
15.16% (6.74%) 121.13% 90.05%
Return on Tangible Assets
(2.02%) (13.50%) 50.16% 62.72%
Average Days of Receivables
86.49 97.05 38.30 41.66
Free Cash Flow per Share
(3.62) (5.85) 8.83 5.69
Free Cash Flow
(300.25) (482.67) 702.41 446.32
Other line items

Show all line items

Columns are period end dates